|
1）Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol. 2008; 9: 61-72
|
|
|
|
2）高野幸路．膵神経内分泌腫瘍の最新の知見．膵内分泌腫瘍におけるソマトスタチン受容体とオクトレオチド．膵臓．2008;23:710-5
|
|
|
|
|
3）Madoff DC, Gupta S, Ahrar K, et al. Update management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006; 17: 1235-50
|
|
|
|
|
|
4）Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol. 2012; 47: 941-60
|
|
|
|
|
|
5）五十嵐久人，伊藤鉄英，船越顕博．mTOR阻害薬．肝胆膵．2009; 59: 1031-7
|
|
|
|
|
|
6）Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate –grade neuroendocrine tumors: results of a Phase II study. J Clin Oncol. 2008; 26: 4311-8
|
|
|
|
|
|
7）Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol. 2010; 28: 69-76
|
|
|
|
|
|
8）Yao JC, Shah M, Ito T, et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med. 2011; 364: 514-23
|
|
|
|
|
|
9）Ito T, Okusaka T, Ikeda M, et al. Everolimus for advanced pancreatic neuroendocrine tumors: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol. 2012; 42: 903-11
|
|
|
|
|
|
10）Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009; 360: 195-7
|
|
|
|
|
|
11）Wiedmann MW, Mossner J. Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors. Clin Med Insights Oncol. 2012; 6: 381-93
|
|
|
|
|
|
12）Kulke MH, Lens H, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008; 26: 3403-10
|
|
|
|
|
|
13）Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. Engl J Med. 2011; 364: 501-13
|
|
|
|
|
|
14）Ito T, Okusaka T, Nishida T, et al. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs. 2012. [Epub ahead of print]
|
|
|
|
|
|
15）Fazio N, Cinieri S, Lorizzo K, et al. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.Cancer Treat Rev. 2010; 3653: 587-94
|
|
|
|
|
|
16）Wolin EM. PI3L/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett. 2013; 335: 1-8
|
|
|
|
|
|
17）The NCCN clinical practice guidelines in oncology for neuroendocrine tumors version 1. 2013
|
|
|
|
|
|
18）Yao JC, Phan AT, Jehl V, et al. Everolimus in advanced pancreatic neuroendocrine tumors: The clinical experience. Cancer Res. 2013; 73: 1449-53
|
|
|
|
|
|
19）Moertel CG, Hanley JA, Johnson LA.Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Eng J Med. 1980; 303: 1189-94
|
|
|
|
|
|
20）Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Eng J Med. 1992; 326: 519-23
|
|
|
|
|
|
21）Lombard-Bohas C, Van Cutsem E, Capdevila J, et al. Update survival and safety data from the Radiant-3 a randomized, double-blind, placebo-controlled, multicenter, phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET). Eur J Cancer. 2011; 47 Suppl 1: 487
|
|
|
|
|
|
22）Vink A, Van Cutsem E, Niccoli P, et al. Update results from a phase III traial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). J Clin Oncol. 2012; 30. [Suppl abstr 4118]
|
|
|
|
|
|
23）Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010; 40: 313-8
|
|
|
|
|
|
24）Bollard J, Couderc C, Blanc M, et al. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas. Neuroendocrinology. 2013; 97: 331-40
|
|
|
|
|